Lumipulse proved successful in a clinical trial. Before earning FDA clearance, a clinical trial tested the blood samples of 499 cognitively impaired adults to evaluate them for Alzheimer’s disease.

Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...

Despite concerns raised by clinicians and ethicists, direct-to-consumer testing for Alzheimer’s disease biomarkers is here, ...

Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance earlier this year. | The Lumipulse G blood test measures the ratio between ...

The FDA has cleared Lumipulse, the first-ever blood test for early Alzheimer's detection, reducing the need for costly and invasive procedures.

The Lumipulse Alzheimer's blood test is the first of a new generation of tests that may replace brain scans ... The FDA has approved two Alzheimer's drugs targeting amyloid plaques in adults with ...

The FDA found that the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio is substantially equivalent to the Lumipulse G β-amyloid Ratio (1-42/1-40), ...

The US Food and Drug Administration (FDA) has granted 510(k) clearance to the first blood test to aid in diagnosing Alzheimer’s disease (AD). The Lumipulse G pTau217/Beta-Amyloid 1-42 Plasma ...

The FDA has approved the first blood test to detect signs of Alzheimer’s disease, marking a major step toward easier diagnosis. The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio test ...

Fujirebio's test works with the company's Lumipulse equipment, which the company says is already "widely available in clinical laboratories" around the U.S. Fujirebio describes Lumipulse as a ...

The test is called the “Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio” and is developed by the Japanese company Fujirebio Diagnostics… The Food and Drug Administration (FDA) ...